Dynavax names new CEO
This article was originally published in Scrip
Dynavax Technologies, a biopharmaceutical company developing products to prevent and treat infectious and inflammatory diseases, has appointed Eddie Gray chief executive officer and a member of its board of directors, effective 1 May 2013. Before joining Berkeley, California-based Dynavax, Mr Gray served as president of pharmaceuticals Europe at big pharma GlaxoSmithKline. He succeeds Dr Dino Dina as CEO of the Dynavax. Dr Dina will remain a consultant to the firm for the transitional period and plans to continue to serve on the company's board. Additionally, Dr Tyler Martin, president, is departing from Dynavax on 31 May 2013.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.